- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04447911
Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia (EMPOWER)
Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia - a Multicentric Randomized Double-blind Placebo-controlled Trial (the EMPOWER Study)
Hyponatremia is the most common electrolyte derangement occurring in hospitalized patients. It is usually classified as hypovolemic, euvolemic or hypervolemic. The most common aetiology of euvolemic hyponatremia is the syndrome of inappropriate antidiuresis (SIAD). Hypervolemic hyponatremia is common in patients with congestive heart failure (CHF) (10-27%) and liver cirrhosis (up to approximately 50%). In SIAD, the regulation of arginine vasopressin (AVP) secretion is impaired which leads to free water retention. In CHF and liver cirrhosis, the effective arterial blood volume is decreased leading to non-osmotic baroreceptor mediated AVP release and consecutive free water retention.
Current treatments of euvolemic and hypervolemic hyponatremia, including the most used treatment fluid restriction, are of limited efficacy. Sodium-Glucose-Co-Transporter 2 (SGLT2) inhibitors reduce glucose reabsorption in the proximal tubule, resulting in glucosuria and consecutive osmotic diuresis. A placebo-controlled randomized trial of our group has shown that a short-term, i.e. a 4-days administration of the SGLT2 inhibitor empagliflozin (Jardiance)® in addition to fluid restriction was effective in increasing the serum sodium concentration in 87 patients with SIAD-induced hyponatremia. The effect of empagliflozin (Jardiance)® without additional fluid restriction is however not yet known. Large randomized controlled trials have shown that SGLT2 inhibitors reduced hospitalization for heart failure in patients with, and more recently without type 2 diabetes. No studies have investigated the effect of SGLT2 inhibitors in hypervolemic hyponatremia.
To evaluate the effect of empagliflozin (Jardiance)® in eu- and hypervolemic hyponatremia, a randomized placebo-controlled study is needed.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Mirjam Christ-Crain, Prof
- Phone Number: +41 61 328 70 80
- Email: Mirjam.Christ-Crain@usb.ch
Study Locations
-
-
-
Basel, Switzerland, 4031
- Recruiting
- University Hospital Basel
-
Contact:
- Sophie Monnerat, MD
- Phone Number: 0041 61 328 76 08
- Email: sophie.monnerat@usb.ch
-
Luzern, Switzerland, 6000
- Recruiting
- Kantonsspital Luzern
-
Contact:
- Stefan Fischli, MD
- Phone Number: + 41 41 205 51 03
- Email: stefan.fischli@luks.ch
-
-
Vaud
-
Lausanne, Vaud, Switzerland, 1011
- Recruiting
- Centre Hospitalier Universitaire Vaudois (CHUV)
-
Contact:
- Anne Zanchi, MD
- Phone Number: +41 21 314 11 11
- Email: anne.zanchi@chuv.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- chronic eu- OR hypervolemic non hyperosmolar (<300 mOsm/kg) hyponatremia (heparin plasma sodium <135 mmol/L on day of inclusion)
Exclusion Criteria:
- known hypersensitivity or allergy to class of drugs or the investigational product,
- severe symptomatic hyponatremia in need of treatment with 3% NaCl-solution or in need of intensive/intermediate care treatment at time of inclusion
- clinical hypovolemia
- Severe reduction of eGFR <20 mL/min/1,73 m2 (KDIGO G4 and G5) or end stage renal disease
- Chronic liver insufficiency with Child Pugh Score ≥10 or decompensated liver cirrhosis (jaundice, hepatorenal syndrome, encephalopathy, bleeding, …)
- Hepatic impairment defined as aspartate transaminase (AST) or alanine transaminase (ALT) >3x the upper limit of normal (ULN); or total bilirubin >2x ULN at time of enrolment
- uncontrolled hypothyroidism
- uncontrolled adrenal insufficiency
- systolic blood pressure <90mmHg
- contraindication for lowering blood pressure
- diabetes mellitus type 1 or pancreatic diabetes mellitus
- treatment with SGLT2 inhibitors, lithium chloride, vaptans, demeclocycline or urea on inclusion day
- severe immunosuppression (leucocytes <2 G/l)
- peripheral arterial disease stage III-IV of the Fontaine Classification
- fasting or other reasons preventing medication intake
- previous enrolment into the current study
- participation in another intervention study
- pregnancy, breastfeeding, intention to become pregnant during the course of the study or lack of safe contraception.
- end of life care
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Empagliflozin
Empagliflozin (Jardiance)® 25mg per os once daily for 30 days
|
Empagliflozin 25mg per os once daily for 30 days
|
Placebo Comparator: Placebo
Placebo (Lactose tablet) per os once daily for 30 days
|
Placebo per os once daily for 30 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in average daily area under curve (AUC) for serum sodium concentration
Time Frame: 4 days
|
Change in average daily AUC for serum sodium concentration
|
4 days
|
Long-term serum sodium change (before/after treatment)
Time Frame: 30 days
|
Absolute change in serum sodium concentration from baseline to end of treatment
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Length of hospital stay
Time Frame: 30 days
|
Length of hospital stay
|
30 days
|
Impact intervention on bodyweight
Time Frame: 30 days
|
change of bodyweight
|
30 days
|
Impact intervention on blood pressure
Time Frame: 30 days
|
change of blood pressure
|
30 days
|
Course of serum sodium level
Time Frame: 30 days
|
Course of serum sodium level
|
30 days
|
Change of plasma osmolality
Time Frame: 30 days
|
Change of plasma osmolality
|
30 days
|
Change of urinary osmolality
Time Frame: 30 days
|
Change of urinary osmolality
|
30 days
|
Change of plasma urea
Time Frame: 30 days
|
Change of plasma urea
|
30 days
|
Change of urinary urea
Time Frame: 30 days
|
Change of urinary urea
|
30 days
|
Change of plasma uric acid
Time Frame: 30 days
|
Change of plasma uric acid
|
30 days
|
Change of urinary uric acid
Time Frame: 30 days
|
Change of urinary uric acid
|
30 days
|
Change of plasma creatinin
Time Frame: 30 days
|
Change of plasma creatinin
|
30 days
|
Change of urinary creatinin
Time Frame: 30 days
|
Change of urinary creatinin
|
30 days
|
Change of plasma potassium
Time Frame: 30 days
|
Change of plasma potassium
|
30 days
|
Change of urinary potassium
Time Frame: 30 days
|
Change of urinary potassium
|
30 days
|
Change in plasma copeptin
Time Frame: 30 days
|
Change in plasma copeptin
|
30 days
|
Change in plasma aldosterone
Time Frame: 30 days
|
Change in plasma aldosterone
|
30 days
|
Change in plasma renin
Time Frame: 30 days
|
Change in plasma renin
|
30 days
|
Change in plasma MR-proANP
Time Frame: 30 days
|
Change in plasma MR-proANP
|
30 days
|
Change in plasma NT-proBNP
Time Frame: 30 days
|
Change in plasma NT-proBNP
|
30 days
|
Change in plasma CTX
Time Frame: 30 days
|
Change in plasma CTX
|
30 days
|
Change in plasma P1NP
Time Frame: 30 days
|
Change in plasma P1NP
|
30 days
|
Occurence of thirst
Time Frame: 30 days
|
Occurence of thirst
|
30 days
|
Occurence of headache
Time Frame: 30 days
|
Occurence of headache
|
30 days
|
Occurence of vertigo
Time Frame: 30 days
|
Occurence of vertigo
|
30 days
|
Occurence of nausea
Time Frame: 30 days
|
Occurence of nausea
|
30 days
|
Change in general well-being
Time Frame: 30 days
|
Change in general well-being according to visual analogue scale
|
30 days
|
Change in quality of life
Time Frame: 30 days
|
change in quality of life according to EQ-5D-5L questionnaire
|
30 days
|
Change in cognitive impairment
Time Frame: 30 days
|
Change in cognitive impairment measured with the MoCa test
|
30 days
|
Change in visual attention
Time Frame: 30 days
|
Change in visual attention measured with the trail making test
|
30 days
|
Change in neuromuscular impairment
Time Frame: 30 days
|
Change in neuromuscular impairment measured with the timed up and go test
|
30 days
|
Change in grip strength
Time Frame: 30 days
|
Change in grip strength measured with a hand dynamometer
|
30 days
|
Occurence of falls
Time Frame: 30 days
|
Occurence of falls
|
30 days
|
Occurence of fractures
Time Frame: 30 days
|
Occurence of fractures
|
30 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Julie Refardt, MD, University Hospital, Basel, Switzerland
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Hepatic Insufficiency
- Metabolic Diseases
- Kidney Diseases
- Urologic Diseases
- Liver Diseases
- Water-Electrolyte Imbalance
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Liver Failure
- Renal Insufficiency
- Hyponatremia
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Sodium-Glucose Transporter 2 Inhibitors
- Empagliflozin
Other Study ID Numbers
- EMPOWER study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Failure
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute Liver FailureIndia
-
Beijing Continent Pharmaceutical Co, Ltd.RecruitingAcute-On-Chronic Liver Failure | Acute Liver FailureChina
-
Tianjin Weikai Bioeng., Ltd.Tianjin Nankai HospitalUnknownLiver Failure, Acute on ChronicChina
-
HLB Cell Co., Ltd.UnknownAcute-On-Chronic Liver Failure | Acute Liver FailureKorea, Republic of
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute Liver Failure | Acute on Chronic Liver FailureIndia
-
Nanfang Hospital of Southern Medical UniversityCompletedLiver Injury | Liver Failure, Acute on Chronic
-
RenJi HospitalNot yet recruiting
-
RenJi HospitalShanghai Institute of Biochemistry and Cell BiologyNot yet recruitingAcute-On-Chronic Liver Failure | Chronic Liver Failure
-
Institute of Liver and Biliary Sciences, IndiaRecruitingAcute on Chronic Liver FailureIndia
-
Cellaion SAActive, not recruitingAcute on Chronic Liver FailureBelgium, Spain, France, Austria, Denmark, Latvia, Germany, Bulgaria, Poland, Estonia, Italy, Lithuania, North Macedonia, Slovakia
Clinical Trials on Empagliflozin 25 MG
-
Instituto Nacional de Cardiologia Ignacio ChavezNot yet recruitingSTEMI | No-Reflow Phenomenon
-
National Taiwan University HospitalShin Kong Wu Ho-Su Memorial HospitalNot yet recruitingHeart Failure With Preserved Ejection Fraction | End Stage Renal Disease on Dialysis
-
University of Sao Paulo General HospitalRecruitingCoronary Artery Disease | Diabetes Mellitus, Type 2 | Acute Kidney Injury | Coronary Artery Bypass SurgeryBrazil
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 2Japan
-
Amsterdam UMC, location VUmcCompleted
-
Yale UniversityBoehringer IngelheimRecruitingEnd Stage Renal Disease on DialysisUnited States
-
University of Mississippi Medical CenterEli Lilly and CompanyRecruiting
-
University Health Network, TorontoRecruiting
-
Tanta UniversityActive, not recruiting
-
Isfahan University of Medical SciencesCompletedDiabetes MellitusIran, Islamic Republic of